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Abstract
Background: Major Depressive Disorder (MDD) is highly prevalent and was associated with greater morbidity, mortality
(including suicide), and healthcare costs. By 2030, MDD will become the leading cause of disability in high-income
countries. Notably, among patients with a previous experience of a major depressive episode, it was indeed estimated
that up to 85 % of those patients will suffer from relapse. Two main factors were associated with a significantly higher risk
of relapse: poor medication adherence and low self-efficacy in disease management. Interestingly, these issues could
become the targets of psychoeducational programs for chronic diseases. Indded psychoeducational program for
depression are recommended in international guidelines, but have not yet been proposed in France.
Methods/Design: We propose to evaluate the first French psychoeducational program for depression “ENVIE” in a
multicenter randomized controlled trial. The group intervention will include 9 weekly sessions. Its aim is to educate
patients on the latest knowledge on depression and effective treatments through didactic and interactive sessions.
Patients will experiment the latest innovating psychological skills (from acceptance and commitment therapy) to cope
with depressive symptoms and maintain motivation in behavioral activation. In total, 332 unipolar non-chronic (<2 years)
outpatients with moderate to severe depression, without psychotic features, will be randomly allocated to the add-on
ENVIE program (N = 166) or to a waiting list (N = 166). The follow-up will last 15 months and include 5 assessment visits.
The primary endpoint will be the remission rate of the index episode at 15 months post-inclusion, defined by a
Montgomery and Asberg Depression Rating Scale (MADRS) score≤ 12 over an 8-week period, and without relapse during
follow-up. We will also assess the response rate and relapse at 15 months post-inclusion, hospitalization rate and
adherence to treatment during the follow-up period, quality of life and global functioning upon inclusion and at 9 and
15 months post inclusion.
Discussion: If the proposed trial shows the effectiveness of the intervention, but also an increased remission rate in
depressed outpatients at 15-months post-inclusion, in addition to improved treatment adherence in patients, it will
further promotes arguments in favor of a wide dissemination of psychoeducational programs for depression.
Trial registration: This trial is registered under number 2015-A00249-40 (PURE clinical trial: NCT02501226)
(June 30th, 2015).
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Background
MDD is associated with a considerable burden on indi-
viduals and societies and a lifetime prevalence of 12 % in
men and 26 % in women [1], MDD ranks as the fourth
disorder having the highest disease burden, accounting
for 40.5 % of DALYs caused by mental disorders [2].
MDD will be the leading cause of disability in high-
income countries by 2030. MDD has been associated
with greater morbidity, mortality (including suicide),
healthcare utilization and costs [3]. Economic costs of
depression have doubled in the past ten years, mainly
due to an increase in indirect costs from loss of product-
ivity [4, 5]. There is a clear need to improve MDD man-
agement without increasing public mental health costs.
Although clinical improvement is often achieved in
60–70 % of depressed patients treated with antidepres-
sants, only about 35 % will reach remission [6, 7]. In
addition to antidepressants, complementary therapeutic
strategies are needed. Furthermore, among patients who
experienced one major depressive episode, it is estimated
that up to 85 % of them will relapse [1]. Moreover, pa-
tients who experienced two episodes, have a 70–90 %
risk of having a third episode [1] The probability of sub-
sequent episodes increases with the number of previous
episodes, with a shorter interval between recurrences
[8]. These data highlight the need to improve preventive
actions to limit depression recurrence. Two main factors
have been associated with a significantly higher risk of
recurrence: poor medication adherence and low self-
efficacy to manage one’s illness (i.e. the patient's confi-
dence in his or her ability to engage in behaviors to
manage and prevent further recurrences) [1]. Interest-
ingly, these two factors are targets of psychoeducational
programs for chronic diseases. Indeed, these types of
programs are designed to educate patients on topics that
are essential and can empower them to become active in
their recovery process through knowledge and informa-
tion. Benefits of empowerment include improved self-
image, self-efficacy, as well as increased ability to cope
with daily life and a higher likelihood of reaching treat-
ment goals [9].
Even if most research on psychoeducation for patients
with mood disorders was conducted in bipolar disorder
[10], international clinical practice guidelines recently
recommended psychoeducational interventions in MDD
[11–13]. Psychoeducation in MDD was shown to: 1) re-
duce depressive symptoms [5, 14–29], 2) reduce the risk
of relapse or recurrence [26, 30–33], 3) improve treat-
ment adherence [17, 18, 34], 4) increase quality of life
[29] and global functionning [25, 35]. In these studies,
the program “Coping with depression” (CWD) was the
most used. CWD is a cognitive behavioral psychoeduca-
tive intervention based on the theory of depression and
social learning [36], which aims at improving self-
esteem, social skills, and management of depressive
thoughts (skills in restructuring negative cognition). A
recent meta-analysis [26] that included 25 randomized
controlled trials showed that CWD was effective in re-
ducing depressive symptoms (overall mean effect size of
0.28 (95 % CI:0.18–0.38)), and in preventing relapses
(overall mean effect size of 0.62 (95 % CI: 0.43–0.91)).
But CWD is complex and requires up to 16 sessions.
Thus, other psychoeducational formats have been devel-
oped: psychoeducational cognitive workshops [14, 15, 19]
and videotaped educational materials [37, 38]. However,
most studies had a short-term follow-up limiting the inter-
pretation of the effectiveness of these psychoeducational
programs on the long-term management of MDD.
To our knowledge, no psychoeducational program
for MDD is available in the French language. Thus,
even though international guidelines recommend inte-
grating a psychoeducational program in MDD treat-
ment, none has yet been made available in France. We
have developed the first French psychoeducational
program for depression called “ENVIE”. This group
intervention consists of 9 weekly sessions. It aims at
teaching patients the latest knowledge on depression
and effective treatments, through didactic and inter-
active sessions. Patients will experiment the last in-
novating psychological skills to cope with depressive
symptoms and maintain their motivation in behavioral
activation [39, 40]. Moreover, the latest innovating
psychological skills, which will be taught in the
“ENVIE” program, belong to Acceptance and Commit-
ment Therapy (ACT) [41]. Interestingly, ACT has
shown equal to superior effectiveness compared to
traditional cognitive behavioral therapy on unipolar
depression [42–45]. Additionally, the specific impact
of ACT skills was recently reported on suicidal risk
[46, 47], which was highly associated with depression.
Finally, patients will become experts and actors in the
management of their disease in order to enhance
treatment adherence, since lack of the latter has been
strongly associated with an increased risk or relapse.
Objective and research questions
Primary objective:
The main objective is to compare the effectiveness
(rate of remission of index episode at 15 months post in-
clusion, without relapse during follow-up) of the add-on
ENVIE psychoeducational program vs. regular treatment
only, in unipolar non-chronic (<2 years) outpatients with
moderate to severe depression, without psychotic
features.
Secondary objectives:
Comparing add-on psychoeducational program with
treatment as usual in regards to:
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– Decrease in depression intensity between inclusion
and at 3, 6, 9 and 15 months post inclusion;
– Response rate 15 months after inclusion;
– Relapse rate 15 months after inclusion;
– Hospitalization rate during the follow-up period;
– Treatment adherence (antidepressants) between
inclusion and at 3, 6, 9 and 15 months after
inclusion;
– Changes in quality of life and global functioning
between inclusion and at 9 and 15 months after
inclusion;
– Modification of psychotropic treatments between
inclusion and at 15 months post inclusion.
Methods
Design
We will conduct a two-arm randomized controlled trial,
in order to compare the effectiveness of add-on psychoe-
ducational program for unipolar depression vs. treat-
ment as usual in depressed outpatients. This trial will
take place in 11 French centers.
Based on medical records, eligible unipolar outpa-
tients suffering from non-chronic (duration of current
episode <2 years) major depressive episode (DSM-IV cri-
teria) of moderate to severe intensity (MADRS score >24)
will first be screened in each center. During the inclusion
visit, participants matching all inclusion criteria and pre-
senting no exclusion criteria will be informed by the investi-
gator and invited to sign a consent form. They will be
randomized in one of the two arms: add-on psychoe-
ducational program (interventional group) or waiting
list (control group). An independent researcher, not
otherwise involved in the study, will perform the allo-
cation. Each patient will be followed during 15 months
with 5 visits: at baseline (V1), 3 months (V2), 6 months
(V3), 9 months (V4) and 15 months (V5) after base-
line. Blinded and trained evaluators will assess patients
during the follow-up.
This research, involving human subjects, has been per-
formed in accordance with the Declaration of Helsinki. The
study protocol has been approved by an appropriate ethics
committee (CPP Sud Méditerranée IV) (covering all
11 participating centres) and is registered under number
2015-A00249-40 (PURE clinical trial: NCT02501226)
(June 30th, 2015).
Sample size
For the control group the full remission rate at
15 months is expected to be 30 % [48]. If, in the experi-
mental group, this rate is 15 % higher, with a power of
0.80 and a two-tailed significance level at 0.05, the sam-
ple size ends up to 166 patients per group. Because loss
to follow-up will be considered as “not in remission”, no
adjusted sample size for taking dropouts into account
has to be established. Thus, a total number of 332 sub-
jects will be enrolled in the study. Each center will re-
cruit between 20 and 40 patients: one to 2
psychoeducational groups of 8–10 patients and 10–20
patients in the control group.
Participants and procedure
Inclusion and exclusion criteria
We will include outpatients [1] aged 18–65 years [2]
with a main diagnosis of non-psychotic non-chronic
(<2 years) major depressive episode (DSM-IV criteria)
of moderate to severe intensity (Montgomery Asberg
Depression Scale score >24) [49] taking at least one
antidepressant [4] able to speak, read and understand
French [5] and able to give written informed consent.
We will exclude subjects [1] with a current diagnosis
of substance abuse or dependence in the 6 months
prior to inclusion, excluding tobacco, [2] current
psychotic features, [49] duration of current depressive
episode >2 years, [4] current organic mental disorder
or mental retardation, or severe comorbid medical
condition, [5] lifetime history of schizophrenia, or
schizoaffective or bipolar disorder, manic, hypomanic,
or mixed episodes according to DSM-IV criteria, [6]
sensory or cognitive disabilities, [7] hospitalized full-
time at the time of inclusion, [8] having a relationship
or being employed by the sponsor or investigator. We
will also exclude patients who are planning a long stay
outside the region preventing compliance with the
scheduled visits, and subjects participating in another
trial.
Recruitment
Participants will be recruited via medical consultations
in the 11 French investigation centers.
Written informed consent will be obtained from
participants.
Eligibility assessment and randomization
People who apply for participation in the study will re-
ceive an information letter with comprehensive details
on study procedures. Signed written informed consent
will be obtained from all participants. They will be in-
formed that they can withdraw from the intervention
and/or study at any time without any negative
consequences.
The first visit will consist in evaluating the following
data:
○ Sociodemographic characteristics: age, gender,
nationality, marital status, educational level,
employment status;
○ Psychopathology using the Mini-International
Neuropsychiatric Interview (M.I.N.I.) [50];
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○ Number of previous depressive episodes, date of
onset of the current episode;
○ Depression intensity using the Montgomery Asberg
Depression Scale (MADRS) and Beck Depression
Inventory (BDI);
○ Global functioning using the Functioning
Assessment Short Test (FAST);
○ Quality of life using the World Health Organization
Quality Of Life measure-26 (WHOQOL-26) scale;
○ History of psychotropic treatment (name, dose);
○ Treatment adherence using the Medication
Adherence Rating Scale (MARS);
○ Lifetime suicidality using the Columbia–Suicide
Severity Rating Scale (C-SSRS).
All inclusion and non-inclusion criteria will be
checked by the study investigator. Patients will then be
informed of their eligibility and randomized with the
Capture Software System (Clinsight). Randomization
will be performed with a permuted-block 1:1 ratio
randomization list with varying block sizes and will be
stratified in participating centers. Allocation conceal-
ment will be achieved by a centralized randomization
procedure via an electronic case-report form.
Assessments
Patients will be assessed by clinicians blinded to treat-
ment allocation, at inclusion (1–3 weeks before the
intervention: visit 1) and at 3 months (end of the psy-
choeducational program: visit 2), 6 months (visit 3),
9 months (visit 4) and 15 months (visit 5) after inclusion.
Patients will be advised to refrain from telling which
group they were allocated to during visits.
See Fig. 1 for a detailed overview.
Investigators should make every effort to minimize the
number of patients lost to follow-up and obtain a max-
imum of information on patients lost to follow-up, par-
ticularly in looking for any adverse events.
To limit patients lost to the touch, participants in the
intervention group will be sent a text message on their
mobile phone (internet-based free site) one day before
each psychoeducational session. Each participant will re-
ceive two text messages: one the week before and the
other the day prior to each follow-up visit.
Intervention
ENVIE: the first French psychoeducational group program
Add-on psychoeducational group program
The intervention will consist of 9 weekly, 90-min ses-
sions led by two trained educators (nurse and medical
doctor). Each group will consist of 8–10 participants.
The ENVIE program will provide participants with the
latest medical knowledge on depression and effective
treatments in a didactic manner [51–57], as well as the
latest innovating psychological skills to cope with de-
pressive symptoms and maintain motivation in behav-
ioral activation [39, 40, 58]. These psychological skills
belong to Acceptance and Commitment Therapy [58].
The program includes 9 sessions, each focusing on a
specific theme or skill:
1. Presentation of the program and the matrix, and
psychotherapeutic tools used during the entire
program to motivate patients to behave in a manner
that is consistent with what is important in their life
[58].
2. Functional analysis of depression using the matrix
(patients are taught to understand which symptoms/
behaviors are linked to depression, why they feel
they are struggling, and what they can do to stop
the struggle)
3. Causes leading to depression
4. Consequences of depression and comorbidities
5. Neurobiological bases of depression
6. Self-analysis of mood state, recognition of prodromal
symptoms of relapse
7. Information about antidepressants, and evidence-
based medical treatments for unipolar depression
8. Lifestyle recommendations
9. Behavioral activation skills
During sessions, participants will be encouraged to
raise questions about anything they want to know
about depression. To enhance the active role of pa-
tients, each session will be followed with take-home
homework.
One or two psychoeducational groups of 8 to 10
patients will be planned in each center.
Treatment as usual
Treatment as usual will consist of the usual clinical
management of depression including psychiatric evalu-
ation and adaptation of pharmacological treatment.
There will be no treatment restriction during the study
period. The current pharmacological treatment will be
recorded at each visit.
Endpoints
Safety endpoints
Incidence, relatedness, and severity of treatment-
emergent adverse events will be evaluated at each visit
until the end of study. Safety parameters assessed in
this clinical trial will be recorded and evaluated
through repeated clinical examinations of the patients.
It relies on assessment of suicidality using the
Columbia–Suicide Severity Rating Scale (C-SSRS)
[59]: rate of suicidal behaviors (completed suicide and
suicide attempts) at 15 months post inclusion,
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variation of severity and intensity of suicidal ideations
subscores between baseline and at 3, 6, 9 and
15 months after inclusion. If a patient exhibits a high-
risk of suicide (increased suicide ideations, planning a
suicide attempt) during a visit, investigators will con-
tact the psychiatrist in charge of this patient.
Moreover, acceptability will be assessed. It will consist
in the number of missed sessions, and satisfaction at
3 months post inclusion using a Likert scale ranging




Remission rate of the index episode at 15 months after
inclusion, defined by a Montgomery and Asberg Depres-
sion Rating Scale (MADRS) [60] score ≤ 12 for over 8-
weeks, without relapse during the follow-up period.
Secondary endpoints
– Variation of the depression intensity between
baseline, and at 3, 6, 9 and 15 months after inclusion
Fig. 1 Study flow
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using MADRS and Beck Depression Inventory (BDI)
[60, 61];
– Evolution of MADRS and BDI scores during
follow-up;
– Response rate (50 % decrease in MADRS score) at
15 months after inclusion;
– Relapse rate (MADRS >12 after remission of the
index episode) at 15 months after inclusion;
– Hospitalization rate during follow-up;
– Variation of global functioning, using the
Functioning Assessment Short Test (FAST) [62],
between baseline, and at 9 and 15 months after
inclusion;
– Variation of quality of life using the World Health
Organization Quality Of Life measure-26
(WHOQOL-26) scale [63] between baseline, and
at 9 and 15 months after inclusion;
– Variation of treatment adherence using the
Medication Adherence Rating Scale (MARS) [64]
between baseline and 15 months after inclusion;
– Variation of benzodiazepines doses between baseline
and at15 months after inclusion;
– Discontinuation rate of the antidepressant treatment
at 15 months after inclusion.
Statistical analysis
General statistical considerations
All statistical analyses will be performed using SAS®
(SAS Institute, Cary, NC, USA).
For efficacy variables, we will use a Full Analysis Set,
which will include all randomized subjects with a valid
primary efficacy baseline measurement and at least one
valid primary efficacy measurement. A robustness evalu-
ation using the Completer Set (CS) will also be per-
formed for the primary efficacy variable. The CS is a
subset of the FAS and will include all subjects with a
valid measurement at the end of the study Period
(15 months) for the primary efficacy variable.
A summary of demographic data and baseline charac-
teristics, as well as medical and procedure history will be
presented for the whole population (all treatment groups
combined) and for each treatment group. For continu-
ous variables, summary statistics (n [number of available
measurements], arithmetic mean, standard deviation
[SD], median, interquartiles, minimum, and maximum)
will be tabulated. For descriptive statistics of continuous
variables, change from baseline and each time point will
be displayed.
Frequency tables (frequency counts and percentages)
will be presented for categorical data.
Primary outcome
The outcome of interest is the probability of remission
achievement (rate of remission) of the index episode at
15 months post inclusion. Time to remission is defined
as the number of days between the date of inclusion and
remission or the last follow-up visit in case of no remis-
sion (maximum duration: 15 months). But the exact
time of this event will not be known (the event could
occur during the interval of two visits), so we will use
methods for the analysis of interval-censored data. For
calculation, all patient lost to follow-up will be consid-
ered as not in remission. A Cox proportional hazard
model will be used to assess the impact of the interven-
tion (Effect size). Covariates could be added in the Cox’s
proportional hazards regression model if both groups
cannot be compared on baseline characteristics alone.
The adjusted hazard ratios and their 95 % confidence
interval will be reported.
Secondary outcomes
The rate of response (decrease of MADRS score by
50 %), and rate of relapse (MADRS >12 after remission
of the index episode) at 15 months after inclusion will
be analyzed with the similar method used for the main
criterion.
A mixed-model will be used to analyze:
1. Variations (intra- and between-group) of depression
intensity using MADRS and BDI scores between
inclusion, and at 3, 6, 9 and 15 months after inclusion.
2. And model the evolution of MADRS and BDI scores
during follow-up
3. Variations (intra- and between-group) of global
functioning (using the FAST) between inclusion, and
at 9 and 15 months after inclusion,
4. Variations of quality of life using WHOQOL-26 scale
between inclusion, and at 9 and 15 months after
inclusion,
The rate of relapse (MADRS >12 after remission of
the index episode) at 15 months after inclusion, the rate
of hospitalization during follow-up and the discontinu-
ation rate of antidepressant therapy at 15 months after
inclusion will be analyzed using a chi-square test or
Fisher’s exact test if the chi-square is not valid.
The between-group comparison on variation in treat-
ment adherence using MARS and changes in benzodiaz-
epines doses between inclusion and 15 months post
inclusion will be performed using the student-t test if
distribution is normal or the Mann–Whitney test, if
otherwise.
Safety analyses
For the analysis of safety data (AEs, vital signs), RS will
be used. Adverse events occurring during this study will
be presented by system organ class (SOC), high level
term (HLT), and preferred term [65] in a frequency table
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giving the number of events, number of subjects, and
percentage of subjects who experienced the event by
treatment group.
Subjects with multiple AEs will be counted only once
within each PT, HLT, and SOC. Coding of the AEs will
be performed with the Medical Dictionary for Regulatory
Activities.
Vital signs variables and their changes from Baseline
will be presented using descriptive statistics by visit and
treatment group.
Rate of suicidal behaviors (completed suicide and sui-
cide attempts) at 15 months after inclusion, variation of
severity and intensity of suicidal ideations subscores
between inclusion and at 3, 6, 9 and 15 months after
inclusion will be reported for each group.
Discussion
Major Depressive Disorder is a highly prevalent disorder
associated with a considerable loss of quality of life, in-
creased mortality rates, and substantial economic costs.
However, because of a lack of knowledge about this dis-
ease, many patients remain untreated although they
need help. Also, among patients treated with adequate
medication, only 35 % will reach remission. Further-
more, the probability of MDD increases with the num-
ber of previous episodes, and the interval between
recurrences does decrease with each new episode. How-
ever, two main factors associated with a significantly
higher risk of relapse are: poor treatment adherence and
low self-efficacy to manage depression, which are the
primary targets in psychoeducation. Thus, psychoeduca-
tion has shown its effectiveness in reducing depressive
symptoms and the risk of relapse or recurrence and in
increasing patients’ quality of life and global functioning.
Moreover, psychoeducation is a simple add-on treat-
ment, which can be delivered by any healthcare profes-
sional thus reducing costs and increasing the number of
patients able to benefit from this program. Currently,
few programs have been developed and those are mainly
available in the English language.
This study will evaluate the effectiveness of the first
French psychoeducational program associated with
treatment as usual, via the rate of remission on de-
pressed outpatients at 15 months of follow-up. A spe-
cial emphasis will be given to teaching didactically the
latest scientific knowledge about depression and ef-
fective treatments, and the latest innovating psycho-
logical skills to cope with depressive symptoms and
maintain motivation in behavioral activation. Notably,
psychological skills stem from Acceptance and Com-
mitment Therapy, which is a brief integrative therapy
(third wave behavior therapy, motivational interview-
ing, and existential therapy) with validated effective-
ness on depression and suicidal risk. Finally, the
ENVIE program has already been conducted in the
primary investigator centre, showing high adherence
and satisfaction rates.
This study will have some limitations. First, as in most
longitudinal studies we will need to deal with the prob-
lem of missing values. Thus, since loss to follow-up will
be considered as “not in remission”, positive results from
this study will be particularly relevant. In order to limit
patients lost to follow-up, participants in the interven-
tion group will be sent a text message on their mobile
phone one day before each psychoeducational session,
and one week and one day before each follow-up visit.
Second, patients will be randomized, but there is no
double-blind, randomization since the patient will know
if he/she belongs to the intervention or control group.
Indeed, the control group will consist of a waiting list,
and not a control group therapy. Third, we will not have
any control over the treatment as usual in each of the
two groups.
There will also be several strengths to this study, in-
cluding the strong methodology of a randomized con-
trolled design, validated assessments conducted by
independent raters blinded to treatment condition, a
sample defined by a standard diagnostic measure, an
appropriate statistical analysis plan, and considering
patients lost to follow-up as not in remission. Further-
more, the long-term follow-up (15 months), the as-
sessment of remission and treatment adherence, and
the latest innovative scientific didactic content of this
short-duration program are highly relevant in these
studies. Given these strengths, the results of the study
should further enhance the evidence-based data sup-
porting psychoeducational intervention for MDD.
Finally, given the 11 French investigator centers im-
plied in this study, the results could be easily general-
ized to depressed patients visiting French medical
centers.
Conclusion
To overcome the gap between the need for treatment
and evidence-based treatment availability and utilisa-
tion, cost-effective low-threshold interventions are
strongly needed to be accessible to as many people as
possible. Psychoeducation is one of them. In fact, a
psychoeducational program seems the most available
strategy to improve treatment adherence and self-
efficacy to manage depression, two main factors asso-
ciated with the risk of relapse. If the proposed trial
shows not only the effectiveness of enhancing the rate
of remission in depressed outpatients at 15 months
follow-up but also improved treatment adherence in
these patients, it would further strengthen the argu-
ments for a wide dissemination of psychoeducational
programs for depression.
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